Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference-Reference-Cited by-同舟云学术

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Published:2020-09-09 Issue:S1 Volume:73 Page:158-191
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Llovet Josep M.¹²³^ORCID,Villanueva Augusto¹^ORCID,Marrero Jorge A.⁴,Schwartz Myron¹,Meyer Tim⁵,Galle Peter R.⁶,Lencioni Riccardo⁷⁸,Greten Tim F.⁹^ORCID,Kudo Masatoshi¹⁰^ORCID,Mandrekar Sumithra J.¹¹,Zhu Andrew X.¹²¹³^ORCID,Finn Richard S.¹⁴,Roberts Lewis R.¹⁵^ORCID,

Affiliation:

1. Mount Sinai Liver Cancer Program Division of Liver Diseases Tisch Cancer InstituteIcahn School of Medicine at Mount Sinai New York NY

2. Translational Research in Hepatic Oncology, Liver Unit IDIBAPS, Hospital ClinicUniversity of Barcelona Barcelona Spain

3. Institució Catalana d’Estudis Avançats (ICREA) Barcelona Spain

4. UT Southwestern Medical Center Dallas TX

5. Department Oncology University College London Cancer Institute London UK

6. Department of Internal Medicine Mainz University Medical Center Mainz Germany

7. Department of Radiology University of Pisa School of Medicine Pisa Italy

8. Miami Cancer Institute Miami FL

9. Gastrointestinal Malignancy Section Thoracic and Gastrointestinal Oncology Branch Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda MD

10. Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

11. Department of Health Sciences Research Mayo Clinic Rochester MN

12. Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA

13. Jiahui International Cancer Center Shanghai China

14. Geffen School of Medicine at UCLA Los Angeles CA

15. Gastroenterology & Hepatology Department Mayo Clinic Rochester MN

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31327

Reference200 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Hepatocellular Carcinoma

3. EASL clinical practice guidelines: management of hepatocellular carcinoma;Galle PR;J Hepatol,2018

4. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

5. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

Cited by 285 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study;JHEP Reports;2024-09

3. Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis;Cancers;2024-08-10

4. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy;Frontiers in Immunology;2024-08-07

5. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial – Authors' reply;The Lancet;2024-08